Boston Scientific’s proposed $230m acquisition of MI Tech is not going to happen.
In June 2022, Boston Scientific announced a definitive agreement to purchase 64% of Korea-based MI Tech from Synergy Innovation for...
Minute Insight: Boston Scientific Walks Away From MI Tech Deal, Citing Regulatory Hurdles
Listen to this article
The Federal Trade Commission said it supports Boston Scientific’s decision to walk away from a planned $230m acquisition of Korea-based MI Tech. Boston Scientific said it could not obtain needed global regulatory approvals.
Keep up with the top medtech business and regulatory news.
More from Minute Insights
- • By
Haemonetics will acquire Quebec-based OpSens for CAD $2.90 per share, or about US $253m at current exchange rates. Haemonetics expects OpSens' fiber-optic technology to complement its interventional cardiology portfolio.
- • By
The retail giant will sell the Dexcom G7 continuous glucose monitoring system to eligible customers through a new online platform.
- • By
Stimdia is trying to restore respiratory function in ICU patients with phrenic nerve stimulation.
- • By
Reuters reported that global private equity firm Carlyle Group has offered to pay at least $7bn for Medtronic’s patient monitoring and respiratory interventions businesses. Medtronic announced its plan to get out of those businesses about one year ago.
More from Medtech Insight
- • By
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
- • By
Class III devices and panel-track supplements approved by US FDA’s Center for Devices and Radiological Health. Data derived from FDA.gov. Updated weekly.
- • By
AdvaMed president Scott Whitaker said the group is focused on the need for tariff stability in conversations with the Trump administration. The organization remains optimistic about other policy areas. New chairman and ResMed CEO Mick Farrell laid out his five priorities.
